Lung Cancer Gene-Edited Cell Lines for Drug Discovery

Lung cancer remains the leading cause of cancer-related death worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020 (WHO GLOBOCAN). The 5-year survival rate for all stages combined is approximately 22% in the United States (NCI SEER), dropping to 7% for distant-stage disease. Major risk factors include tobacco smoking, radon exposure, occupational carcinogens, and air pollution. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, with adenocarcinoma and squamous cell carcinoma as the predominant subtypes.

Lung cancer is an ideal model for mechanistic studies due to its well-characterized molecular subtypes, extensive public genomic datasets (TCGA, COSMIC), and a high prevalence of actionable driver mutations. Key open questions include mechanisms of acquired resistance to targeted therapies, tumor heterogeneity, and immune evasion. Gene-edited cell models enable precise dissection of these mechanisms.

Lung carcinogenesis involves multiple pathways:

• • EGFR/RAS/RAF/MEK/ERK (MAPK) pathway: Constitutive activation via mutations in EGFR (exon 19 deletions, L858R) or KRAS (G12C, G12D, G12V).
• • PI3K/AKT/mTOR pathway: Activation through PIK3CA mutations or PTEN loss.
• • TP53 pathway: Loss-of-function mutations in TP53 (present in ~50% of NSCLC) leading to impaired apoptosis and genomic instability.
• • Cell cycle regulation: CDKN2A loss or RB1 inactivation leading to uncontrolled proliferation.

Data from TCGA Pan-Lung Cancer (Nature 2014) and COSMIC v99.

Key deregulated networks in lung adenocarcinoma:

• • MAPK signaling: KRAS, BRAF, MEK1/2, ERK1/2
• • PI3K/AKT signaling: PIK3CA, AKT1, PTEN, mTOR
• • DNA damage response: TP53, ATM, ATR, CHEK2
• • Oxidative stress response: KEAP1, NRF2, SQSTM1
• • Cell cycle: CDKN2A, CDK4, CCND1, RB1

These networks are interconnected and often co-mutated, driving tumor progression and therapy resistance.

Commonly used lung cancer cell lines:

Organoid models derived from patient tumors retain 3D architecture and heterogeneity, offering advantages for drug testing and personalized medicine.

In vivo models for lung cancer research:

• • Patient-derived xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice; preserves tumor heterogeneity.
• • Genetically engineered mouse models (GEMM): Conditional Kras G12D; Trp53 null (KP model) recapitulates human adenocarcinoma.
• • Induced models: Carcinogen-induced (urethane, NNK) tumors in mice.
• • Syngeneic models: Mouse lung cancer cell lines (e.g., LLC) implanted into immunocompetent mice for immunotherapy studies.

CRISPR/Cas9 gene editing enables the generation of isogenic cell lines with precise genetic modifications. Examples include TP53 knockout in A549 cells, KRAS G12C knock-in in H1299 cells, and EGFR T790M knock-in in PC9 cells. These models allow direct comparison of mutant vs. wild-type phenotypes in an identical genetic background. Commercially available, sequence-verified CRISPR knockout and knock-in cell lines accelerate research by eliminating the need for in-house editing and validation.

Gene-edited cell lines are essential for validating candidate driver genes identified by genomic studies. For example, CRISPR-mediated knockout of KEAP1 in A549 cells confirmed its role in oxidative stress resistance. Knock-in of KRAS G12C in wild-type lung epithelial cells demonstrated oncogenic transformation and MAPK pathway activation.

Isogenic cell pairs (e.g., EGFR wild-type vs. EGFR L858R/T790M) are used in high-throughput screens to identify selective inhibitors. Resistance mechanisms can be modeled by chronic drug exposure in gene-edited lines, revealing secondary mutations (e.g., EGFR C797S) or bypass signaling (e.g., MET amplification).

CRISPR-based synthetic lethality screens in lung cancer cell lines identify vulnerabilities specific to mutant genotypes. For example, KRAS-mutant cells are sensitive to inhibition of the MAPK pathway or autophagy. Gene-edited models enable validation of candidate biomarkers for patient stratification.